uniQure

ISIN NL0010696654

 | 

WKN A1XDTV

Market cap (in EUR)
915 m
Country
Netherlands
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Netherlands

Financials

Key metrics

Market capitalisation, EUR 915 m
EPS, EUR -3.08
P/B ratio 5.4
P/E ratio -
Dividend yield 0.00%

Income statement (2025)

Revenue, EUR 14 m
Net income, EUR -176 m
Profit margin -1,236.00%

What ETF is uniQure in?

There are 5 ETFs which contain uniQure. All of these ETFs are listed in the table below. The ETF with the largest weighting of uniQure is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
JPMorgan Active US Growth UCITS ETF USD (acc) 0.02%
Equity
United States
Growth
333
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.08%
Equity
United States
Health Care
Biotech
48
JPMorgan Active US Growth UCITS ETF USD (dist) 0.02%
Equity
United States
Growth
1
JPMorgan Active US Growth UCITS ETF EUR Hedged (acc) 0.02%
Equity
United States
Growth
9
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.01%
Equity
United States
Small Cap
189
— Les données utilisées sont mises à disposition par Trackinsight, etfinfo, Xignite Inc., gettex, FactSet et justETF GmbH.

Les cotations sont des cotations en temps réel (gettex), des cotations boursières retardées de 15 minutes ou des VNI (quotidiennes publiées par le fournisseur du fonds). Par défaut, les rendements des ETF incluent les paiements de dividendes (le cas échéant). Aucune garantie n'est donnée quant à l'exhaustivité, la précision et l'exactitude des informations affichées.